Subscribe To
VTGN / Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript
VTGN News
By Seeking Alpha
August 13, 2023
Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Sh more_horizontal
By Schaeffers Research
August 10, 2023
Outperforming Biotech Pops on Shareholder Buzz
Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Mast more_horizontal
By InvestorPlace
August 7, 2023
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer more_horizontal
By PennyStocks
August 7, 2023
VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why
Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are more_horizontal
By Business Wire
June 27, 2023
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming more_horizontal
By Seeking Alpha
February 10, 2023
VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice Presi more_horizontal
By Zacks Investment Research
February 7, 2023
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. D more_horizontal
By Business Wire
February 6, 2023
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treat more_horizontal